Assessing-and Extending-California's Insulin Manufacturing Initiative.

This Viewpoint reviews California's recently proposed CalRx initiative to manufacture biosimilar insulin, highlights challenges facing the initiative, and suggests ways in which, if successful, the initiative could serve as a model for state-managed development of drugs other than insulin, reduce drug prices, and provide other benefits.